NEOFECT® Reagents

NEOFECT® 转染试剂

新一代非脂质体转染试剂,以阳离子聚合物为主要成分。试剂与核酸形成稳定复合物,透过细胞膜进入细胞并保护核酸免受核酸酶降解;对细胞毒性小,含血清完全培养基中可直接使用。

查看详情
DNA 转染

NEOFECT® DNA 转染试剂

NEOFECT® DNA transfection reagent
  • 低细胞毒性——10 倍使用浓度下仍无明显细胞毒性
  • 高转染效率——在多数细胞中优于脂质体转染试剂
  • 用量经济——1 μg DNA : 1 μL 试剂等量混合
  • 操作简单——三步完成,一般无需换液
货号 TF20121201规格 1 mL目录价 ¥ 1,800
使用说明
siRNA 转染

NEOFECT® siRNA 转染试剂

NEOFECT® siRNA transfection reagent
  • 专用于 siRNA 转染,转染效率高
  • 细胞毒性低,无需换液
  • 在多种细胞系及原代细胞中表现良好
  • 按 NEOFECT® : siRNA = 1 : 1 体积比混合
货号 TF20141402规格 750 μL目录价 ¥ 1,800
使用说明
细胞培养配套

NEOFECT+ 支原体去除试剂

NEOFECT+ Mycoplasma removal reagent
  • 广谱、低毒、高效的新型支原体去除试剂
  • 原液 1000× 稀释至 1× 使用,可直接加入培养基
  • 每 3~4 天换液,持续处理 2 周
  • 相比商用对比试剂细胞毒性更小
货号 ME201901规格 200 μL目录价 ¥ 200
使用说明
About

关于码因科技

码因科技以细胞基因递送技术为基础能力,致力于成为高通量功能基因组学的基础产品提供商,为科研用户提供从基因递送到文库筛选的关键工具。

自 2014 年以来,使用 NEOFECT® 转染试剂完成的研究已累计被近 1000 篇文献引用,其中不乏发表于 Nature 等顶级期刊的工作。以下为部分代表性文献。

Nature 649, 423–431 (2026)

Adenosine signalling drives antidepressant actions of ketamine and ECT

腺苷信号通路介导氯胺酮与电休克疗法的抗抑郁作用

Chenyu Yue, Na Wang, …, Xiaohui Wang & Minmin Luo(北京脑科学与类脑研究所 等)

论文方法部分标注了所用转染试剂:

At 60–70% confluency, cells were transfected with the GRABAdo1.0 plasmid using Neofect DNA transfection reagent (Neofect Biotech).
Nature · Methods
doi.org/10.1038/s41586-025-09755-9
  1. Sun L, …, Shi Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. PNAS, 2017.
  2. Peng S, …, Deng H, Zhou X. Metal-organic frameworks for precise inclusion of single-stranded DNA and transfection in immune cells. Nature Communications, 2018.
  3. Hu X-L, …, Shen Q. Persistent expression of VCAM1 in radial glial cells is required for the embryonic origin of postnatal neural stem cells. Neuron, 2017.
  4. Ma C, …, Niu Y, Song S, Tong W-M. RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum. Genome Biology, 2018.
  5. Mu L, …, Xia T, Shi Y. A phosphatidylinositol 4,5-bisphosphate redistribution-based sensing mechanism initiates a phagocytosis programing. Nature Communications, 2018.
  6. Sha L, …, Shen Y, Xu Q. Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy. Journal of Experimental Medicine, 2017.
  7. Zhou R, …, Shi Y. Dominant negative effect of the loss-of-function γ-secretase mutants on the wild-type enzyme through heterooligomerization. PNAS, 2017.
  8. Liu S, …, Wang X. Systematic identification of regulatory variants associated with cancer risk. Genome Biology, 2017.
  9. Chen J, …, Shi Y. Strong adhesion by regulatory T cells induces dendritic cell cytoskeletal polarization and contact-dependent lethargy. Journal of Experimental Medicine, 2017.
  10. Sun R, …, Zhang F-L, Shao Z-M, Li D-Q. FBXO22 possesses both protumorigenic and antimetastatic roles in breast cancer progression. Cancer Research, 2018.
  11. Shentu Y-P, …, Man H-Y, Liu R. CIP2A causes Tau/APP phosphorylation, synaptopathy, and memory deficits in Alzheimer’s disease. Cell Reports, 2018.
  12. Hong D, …, Chen Y. Deletion of TMEM268 inhibits growth of gastric cancer cells by downregulating the ITGB4 signaling pathway. Cell Death & Differentiation, 2018.

先试用,再决定

提供 DNA / siRNA 转染试剂与 NEOFECT+ 支原体去除试剂试用装申请,并欢迎索取 SOP 与质控报告样本。CRISPR Screen 文库及相关服务可另行沟通。

联系我们